**Telephone facilities in New Bombay**

*75. SHRIMATI SUDHA VIJAY JOSHI: Will the Minister of COMMUNICATIONS be pleased to state:

(a) whether, in view of the gradual shifting of some economic activities from Bombay to New Bombay, the telephone communication system is being enlarged in New Bombay;

(b) if so, what schemes have been drawn up for improving local dialling system, provision of new telephone exchanges, telephone cables, ducts etc. in New Bombay; and

(c) the progress made so far in respect of the above works?

THE MINISTER OF COMMUNICATIONS (SHRI BIR BAHADUR SINGH): (a) Yes, Sir.

(b) and (c) Comprehensive development plan for improving telephone services within New Bombay, from New Bombay to Bombay and other places has been drawn up and depending upon the supply position of the digital switching equipment from M/s. I.T.I. Mankapur, this programme is being implemented. The development programme is an integrated one which includes installation of telephone exchange, laying of under ground cable ducts and telephone cables, subscriber's fittings, etc. These components of the development plan are given in Annexure which is laid on the Table of the House. [*See* Appendix CXLIX Annexure No. 16].

**Report on D.V.C.**

*76. DR. R.K. PODDAR:
SHRI MOSTAFA BIN QUASEM:

Will the Minister of ENERGY be pleased to state

(a) whether the official sub-committee, set up to go into the performance of DVC, has submitted its report; and

(b) if so, what are the detials thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRI KALPNATH RAI): (a) No official Sub-Committee has been set up by the Government to go into the performance of Damodar Valley Corporation.

(b) does not arise.

**Price Decontrol on bulk drugs**

*77. SHRI BHAGATRAM MANHAR:
DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention has been drawn to the news item which appared in the Economic Times on 16th January, 1989, under the heading "Kelkar Panel for lifting price control on 13 drugs";

(b) if so, whether it is a fact that Kelkar Committee recommended for price decontrol of around 30 bulk drugs on the representations of Members of Parliament on the grounds of neligible sales turnover;

(c) is so, what are the names of those drugs;

(d) whether it is a fact that his Ministry has decontrolled some more drugs having substantial turnover, apart from these 30 drugs; and

(e) if so, what are the names of those drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The term of the Committee for identification of Cate-gory-II drugs (called Kelkar Committee) was extended after the notification of DPCO, 1987, for review-

ing any representations received by the Government regarding discripancies, anomalies etc., in the list of drugs under DPCO, 1987. In addition, as per the report of the Committee the Ministry of Health and Family Welfare desired the Kelkar Committee to hear the representations regarding some Category-I drugs also. The said Committee, therefore, reviewed the representations for the drugs in both the Schedules under DPCO, 1987.

2. A number of representations had been received by the Kelkar Committee for either exclusion or for re-categorisation of the drugs manufactured by various companies which were included in the scheduled drugs under DPCO, 1987. These included 83 letters written by 42 Members of Parliament in this connection, who also suggested the inclusion of a number of drugs under the Price Control of DPCO, 1987.

3. In pursuance of the recommendations contained in the Supplementary Report of the Kelkar Committee, the following actions have been taken so far:—

3.1 In terms of S.O. No. 82 (E) dated 18th January, 1989 published in the Gazette of India Extraordinary, of that date:

(a) Four drugs have been transferred from the First Schedule of DPCO, 1987 to the Second Schedule thereof. These are Rifampicin, Paracetamol, Timoll and Sodium Sulphacetamide.

(b) The following 15 drugs have been exempted from Price Control under DPCO, 1987: (i) Amiloride, (ii) Amitryptyline (iii) Chloropromazine, (iv) Diazepam, (v) Fluroazepam, (vi) Glibenclamide, (vii) Imipramine, (viii) Lorazepam, (ix) Menthol (x) Nitrozepam, (xi) Oxazepam, (xii) Prochlorperazine, (xiii) Trifluperazine, (xiv) Triflupremazine (xv) Oral Rehydration Salts (ORS). The last item i.e. O.R.S. was in the First Schedule and the remaining 14 in the Second Schedule. Most of these are Psychotherapeutic Drugs and Tranquilisers and have been deleted in the background of the recommendation of Ministry of Health in this regard made to the Kelkar Committee. All the said 15 drugs, however, form a part of the total number of drugs proposed for price decontrol by the Kelkar Committee.

(c) An enabling provision has been made under para 26(2) of the DPCO,1987 for granting exemption from Price Control where the production of bulk drugs occurs from basic stage by process developed through indigenous Research & Development.

3.2 In background of the enabling provision cited at 3.1 (c) above.

(a) Specific Guidelines for consideration of applications have been issued on 14.2.1989.

(b) An Inter-ministerial Special Committee has been constituted for consideration of the applications.

3.3 Copies of the Gazette Notification dated 18.1.1989 (Annexure-I) the Guide lines (Annexure-II) and the Order constituting the Special Committee (Annexure-III) are enclosed.

4. The remaining recommendations relating to the terms of reference of the Kelkar Committee which relate to the exclusion of some drugs from DPCO, 1987, on account of considerations of low sales turn-over, and inclusion of additional drugs in DPCO, 1987, are yet to be considered by the Government.

**Annexure-I**

MINISTRY of INDUSTRY

(Department of Chemicals & Petro-Chemicals)

Office of the Development Commissioner (PI)

ORDER

*New Delhi, the 18th Jan., 1989*

S.O. 82 (E)— In exercise of the powers conferred by Section 3 of the Essential Commodities Act., 1955 (10 of 1955), the Central Government hereby makes the following order to amend the Drugs (Prices Control) Order, 1987, namely:—

1. (i) This Order may be called the Drugs (Prices Control) Amendment Order, 1989.

(ii) It shall come into force on the date of its publication in the Official Gazette.

2. In paragraph 28 of the said Order under subpara (2) the following entry be inserted, namely:—

"(e) Production of bulk drugs from basic stage by process developed through indigenous Research and Development".

3. In the First Schedule of the said Order:—

(i) Under the heading "I. National T. B. Eradication Programme", Serial No. 7 and the entry relating thereto shall be deleted.

(ii) Under the heading "II. National Leprosy Eradication Programme". serial number 3 and the entry relating thereto shall be deleted.

(iii) Under the heading "III. National Trachoma Control Programme and National Programme for Control of Blindness," serial numbers 2 and 6 and the entries relating thereto shall be deleted and the remaining entries shall be renumbered as"1 to 7".

(iv) The heading "IV. Programme for Prevention of Dehydration under ORT", serial number 1 and the entry relating thereto shall be deleted.

(v) Under the heading "V. National Malaria Eradication Programme", serial number 6 and the entry relating thereto shall be deleted.

(vi) The headings "V" and "VI" shall be renumbered as "IV" and "V".

4. In the Second Schedule of the said order, the following serial numbers and the entries relating thereto shall be deleted, namely:—

"4. Amilóride

6. Amitryptyline

22. Chlorpromazine

27. Diazepam

47. Flurazepam

52. Glibenclamide

65. Imipiramine

70. Lorazepam

76. Menthol

80. Nitrazepam

84. Oxazepam

90. Prochlorperazine

125. Trifluperazine

126. Triflupromazine".

5. In the second Schedule of the said order, after serial number 139 and the entry relating thereto, the following serial numbers and entries shall be inserted, namely:—

"140. Paracetamol

141. Rifampicin

142. Timolol".

6. In the Third Schedule of the said Order, under the heading "2. Category II Formulations," for the existing sub-para (ii), the following shall be substituted, namely:—

"(ii) All single ingredient Vitamin formulations containing individual Vitamins specified in the second

schedule, sold either in brand name or in generic name, except the single ingredient Vitamin formulations based on the bulk drugs Vitamin A and Vitamin C sold in brand name".

No. 4(8)/87-PI (II)

Sd/—

(L.K. MALHOTRA)
Director (PI)

**Annexure-II**

F. No. 4(8)/87-PI(II) Part

GOVERNMENT OF INDIA

**Ministry of Industry**

Department of Chemicals & Petro-Chemicals

Office of the Development Commissioner (PI)

*New Delhi, the 14th Feb., 1989*

GUIDELINES No. 1/1989

In exercise of the powers conferred by Paragraph 25 of the Drugs (Prices Control) Order, 1987, (hereinafter called the "said Order"), the Central Government hereby issue guidelines for the purpose of grant of exemption under Para 28 of the said Order to such bulk drug manufacturing unit from the provisions of Para 3 of the said Order, in respect of such bulk drug(s) as is/are produced by that unit from the basic stage by a process of manufacture developed through its own Research and Development effort, for a specified period not exceeding five years reckoned from the date of commencement of commercial production of such bulk drug(s) subject to the following, namely:—

(i) The process development activities are registered with the Department of Scientific and Industrial Research (hereinafter referred to as DSIR) and a certificate is issued by DSIR to the effect that the manufacturer has developed the process of manufacture through its own R & D efforts.

(ii) The process so developed is significantly different from the known/available technology in the country leading to import substitutions/cost reduction etc.

(iii) The manufacturer shall make an application to the Government within 30 days of commencement of commercial production of such bulk drug or within 30 days of the date of issue of these guidelines in the case of bulk drugs already under production, as the case may be, alongwith the information as per the Annexure and such other information as may be required by the Government and/or such additional information as the company may voluntarily furnish.

(iv) The Government if satisfied with the application mentioned above, may by a Notification in the Official Gazette, exempt a manufacturer from fixation of price or compliance with the price already fixed if any for such a bulk drug under the provisions of the said Order.

(v) In case of bulk drugs which are already being produced from the basic stage by a process of manufacture developed through indigenous Research and Development, the period which has already elapsed since it come into commercial production by this process, shall count towards determining the said limit of five years prescribed under this Order.

(vi) In case of processes developed by National Laboratories and purchased and actually made use of by a manufacturer such activity shall

*also be taken into consideration for the purpose of granting exemption.*

(vii) The Government shall have the liberty to withdraw the exemption so granted at any time.

(viii) After expiry of the period ot exemption, the manufacturer shall submit application(s) in Form-I of the Drugs (Prices Control) Order, 1987 for fixation of price of such a bulk drug(s) under the provisions of the said Order.

Sd/-
(R.S. MATHUR)

Joint Secretary to the Govt. of India

To

1. All Pharmaceutical Industry. Associations

2. B.I.C.P.

CIRCULATED

Sd/-
(L.K. MALHOTRA)
Director (PI)
14.2.1989

[Form-I as per para (viii) of Annexure-II]

[information to be furnished (in five copies) for exemption of bulk drug from price control under Para 28 of DPCO, 1987].

1. Name and address of the applicant:
2. Status and activities;
3. Details of recognition granted by DSIR:

(i) Date of recognition and validity period:

(ii) Research and Development Programmes proposed in the application for recognition with DSIR:

(iii) Date of issue of certificate by DSIR regarding development of processes for the manufacture of bulk drug. (copy to be enclosed).

4. Name of the bulk drug for which exemption is claimed and details of industrial approval held:

5. *Dates of commencement and completion of R & D :*

(i) Laboratory scale
(ii) Pilot scale
(iii) Commercial trials.

6. Date of commencement of commercial production and quantity produced year-wise:

7. Brief details of the process developed:

8. Details of Significant improvements over the processes already available, if any, in the country.

9 Quantity benefits in terms of
(i) Import substitutions
(ii) Cost reduction
(iii) Any other

10. Details of cost date and the proposed price as per Form I A of DPCO, 1987.

11. Any other details in support of the claim for exemption.

(The information furnished in this form is to be certified by the authorised signatory of the Company).

Sd/-
(R.S. MATHUR)

*Joint Secretary to the Govt. of India*

**Annexure - III**

No. F. 4/8/87-PI (II)-PART

GOVERNMENT OF INDIA

**Ministry of Industry**

Department of Chemicals and Petrochemicals

Office of the Development Commissioner (PI)

*New Dehli, the 14th February, 1989.*

MEMORANDUM

It has been decided to constitute the following Expert Committee to examine the applications received from various manufacturers for exemption of bulk drug(s) from Price Control as provided under Paragraph 28(2) (e) of Drugs (Prices Control) Order, 1987:

| | | |
|---|---|---|
| 1. | Shri K.M. Kaul, Project Officer (PI), Department of Chemicals & Petrochemicals, Shastri Bhawan, New Delhi. | Chairman |
| 2. | Dr. Rajendra Prasad, Principal Scientific Officer, Department of Science & Industrial Research, Technology Bhawan, New Mehrauli Road, New Delhi. | Member |
| 3. | Shri Y.B. Telang, Deputy Director, Bureau of Industrial Costs & Prices Lok Nayak Bhawan (7th Floor), New Delhi. | Member |
| 4. | Shri J.M. Garg, Development Officer (Chem.) D.G.T.D., Udyog Bhawan, New Delhi. | Member |

2. The Committee will examine the various application received from time to time and make necessary recommendations.

Sd/-
(R.S. MATHUR)
Joint Secretary to the Govt. of India.

CIRCULATED.

Sd/-
(L.K. MALHOTRA)
DIRECTOR (PI)

To

1. The Members of the Expert Committee.
2. The Concerned Head of the Departments.

**Printing Press of Postal Department**

* 78: DR. RATNAKAR PANDEY:
SHRI CHANDRIKA PRASAD TRIPATHI:

Will the Minister of COMMUNICATIONS be pleased to state:

(a) whether it is a fact that Postal Department does not have its own printing press for printing its various forms etc;

(b) if so, what is the amount annually spent on printing by the Department;

(c) whether the Postal Department proposes to have its own printing press in the near future; and

(d) if so, what are the details thereof?

THE MINISTER OF COMMUNICATIONS (SHRI BIR BAHADUR SINGH): (a) No, Sir.

(b) The amount spent by the Department of Posts on printing in 1987-88 was Rs. 9.17 crores.

(c) and (d) The Department of Posts has already established a modern off-set printing press having two reel printing machines and two sheet fed machines at Bhubaneswar.

**IDPL Drug to cure Arthritis**

*79. SHRI MURLIDHAR CHANDRAKANT BHANDARE:
SHRI MAHENDRA PRASAD:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the Indian Drugs and Pharmaceuticals Limited is producing a new drug to cure arthritis;